Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries

Grace Hui Min Wu, Yi Ming Wang, Amy Ming Fang Yen, Jau Min Wong, Hsin Chih Lai, Jane Warwick, Tony Hsiu Hsi Chen

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: The aim of this study is to compare the cost-effectiveness of screening with stool DNA testing with that of screening with other tools (annual fecal occult blood testing, flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years) or not screening at all. Methods: We developed a Markov model to evaluate the above screening strategies in the general population 50 to 75 years of age in Taiwan. Sensitivity analyses were performed to assess the influence of various parameters on the cost-effectiveness of screening. A third-party payer perspective was adopted and the cost of $13,000 per life-year saved (which is roughly the per capita GNP of Taiwan in 2003) was chosen as the ceiling ratio for assessing whether the program is cost-effective. Results: Stool DNA testing every three, five, and ten years can reduce colorectal cancer mortality by 22%, 15%, and 9%, respectively. The associated incremental costs were $9,794, $9,335, and $7,717, per life-year saved when compared with no screening. Stool DNA testing strategies were the least cost-effective with the cost per stool DNA test, referral rate with diagnostic colonoscopy, prevalence of large adenoma, and discount rate being the most influential parameters. Conclusion: In countries with a low or intermediate incidence of colorectal cancer, stool DNA testing is less cost-effective than the other currently recommended strategies for population-based screening, particularly targeting at asymptomatic subjects.

Original languageEnglish
Article number136
JournalBMC Cancer
Volume6
DOIs
Publication statusPublished - May 24 2006
Externally publishedYes

Fingerprint

Early Detection of Cancer
Cost-Benefit Analysis
Colorectal Neoplasms
Costs and Cost Analysis
DNA
Incidence
Colonoscopy
Taiwan
Health Insurance Reimbursement
Sigmoidoscopy
Occult Blood
Adenoma
Population
Referral and Consultation
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. / Wu, Grace Hui Min; Wang, Yi Ming; Yen, Amy Ming Fang; Wong, Jau Min; Lai, Hsin Chih; Warwick, Jane; Chen, Tony Hsiu Hsi.

In: BMC Cancer, Vol. 6, 136, 24.05.2006.

Research output: Contribution to journalArticle

Wu, Grace Hui Min ; Wang, Yi Ming ; Yen, Amy Ming Fang ; Wong, Jau Min ; Lai, Hsin Chih ; Warwick, Jane ; Chen, Tony Hsiu Hsi. / Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. In: BMC Cancer. 2006 ; Vol. 6.
@article{58a378e2ea264c80a3dac1ef9c0d0d41,
title = "Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries",
abstract = "Background: The aim of this study is to compare the cost-effectiveness of screening with stool DNA testing with that of screening with other tools (annual fecal occult blood testing, flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years) or not screening at all. Methods: We developed a Markov model to evaluate the above screening strategies in the general population 50 to 75 years of age in Taiwan. Sensitivity analyses were performed to assess the influence of various parameters on the cost-effectiveness of screening. A third-party payer perspective was adopted and the cost of $13,000 per life-year saved (which is roughly the per capita GNP of Taiwan in 2003) was chosen as the ceiling ratio for assessing whether the program is cost-effective. Results: Stool DNA testing every three, five, and ten years can reduce colorectal cancer mortality by 22{\%}, 15{\%}, and 9{\%}, respectively. The associated incremental costs were $9,794, $9,335, and $7,717, per life-year saved when compared with no screening. Stool DNA testing strategies were the least cost-effective with the cost per stool DNA test, referral rate with diagnostic colonoscopy, prevalence of large adenoma, and discount rate being the most influential parameters. Conclusion: In countries with a low or intermediate incidence of colorectal cancer, stool DNA testing is less cost-effective than the other currently recommended strategies for population-based screening, particularly targeting at asymptomatic subjects.",
author = "Wu, {Grace Hui Min} and Wang, {Yi Ming} and Yen, {Amy Ming Fang} and Wong, {Jau Min} and Lai, {Hsin Chih} and Jane Warwick and Chen, {Tony Hsiu Hsi}",
year = "2006",
month = "5",
day = "24",
doi = "10.1186/1471-2407-6-136",
language = "English",
volume = "6",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries

AU - Wu, Grace Hui Min

AU - Wang, Yi Ming

AU - Yen, Amy Ming Fang

AU - Wong, Jau Min

AU - Lai, Hsin Chih

AU - Warwick, Jane

AU - Chen, Tony Hsiu Hsi

PY - 2006/5/24

Y1 - 2006/5/24

N2 - Background: The aim of this study is to compare the cost-effectiveness of screening with stool DNA testing with that of screening with other tools (annual fecal occult blood testing, flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years) or not screening at all. Methods: We developed a Markov model to evaluate the above screening strategies in the general population 50 to 75 years of age in Taiwan. Sensitivity analyses were performed to assess the influence of various parameters on the cost-effectiveness of screening. A third-party payer perspective was adopted and the cost of $13,000 per life-year saved (which is roughly the per capita GNP of Taiwan in 2003) was chosen as the ceiling ratio for assessing whether the program is cost-effective. Results: Stool DNA testing every three, five, and ten years can reduce colorectal cancer mortality by 22%, 15%, and 9%, respectively. The associated incremental costs were $9,794, $9,335, and $7,717, per life-year saved when compared with no screening. Stool DNA testing strategies were the least cost-effective with the cost per stool DNA test, referral rate with diagnostic colonoscopy, prevalence of large adenoma, and discount rate being the most influential parameters. Conclusion: In countries with a low or intermediate incidence of colorectal cancer, stool DNA testing is less cost-effective than the other currently recommended strategies for population-based screening, particularly targeting at asymptomatic subjects.

AB - Background: The aim of this study is to compare the cost-effectiveness of screening with stool DNA testing with that of screening with other tools (annual fecal occult blood testing, flexible sigmoidoscopy every 5 years, and colonoscopy every 10 years) or not screening at all. Methods: We developed a Markov model to evaluate the above screening strategies in the general population 50 to 75 years of age in Taiwan. Sensitivity analyses were performed to assess the influence of various parameters on the cost-effectiveness of screening. A third-party payer perspective was adopted and the cost of $13,000 per life-year saved (which is roughly the per capita GNP of Taiwan in 2003) was chosen as the ceiling ratio for assessing whether the program is cost-effective. Results: Stool DNA testing every three, five, and ten years can reduce colorectal cancer mortality by 22%, 15%, and 9%, respectively. The associated incremental costs were $9,794, $9,335, and $7,717, per life-year saved when compared with no screening. Stool DNA testing strategies were the least cost-effective with the cost per stool DNA test, referral rate with diagnostic colonoscopy, prevalence of large adenoma, and discount rate being the most influential parameters. Conclusion: In countries with a low or intermediate incidence of colorectal cancer, stool DNA testing is less cost-effective than the other currently recommended strategies for population-based screening, particularly targeting at asymptomatic subjects.

UR - http://www.scopus.com/inward/record.url?scp=33746659829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746659829&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-6-136

DO - 10.1186/1471-2407-6-136

M3 - Article

VL - 6

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 136

ER -